JP2009529502A5 - - Google Patents

Download PDF

Info

Publication number
JP2009529502A5
JP2009529502A5 JP2008557568A JP2008557568A JP2009529502A5 JP 2009529502 A5 JP2009529502 A5 JP 2009529502A5 JP 2008557568 A JP2008557568 A JP 2008557568A JP 2008557568 A JP2008557568 A JP 2008557568A JP 2009529502 A5 JP2009529502 A5 JP 2009529502A5
Authority
JP
Japan
Prior art keywords
dosage form
form according
scyllo
inositol
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008557568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529502A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2007/000395 external-priority patent/WO2007101353A1/en
Publication of JP2009529502A publication Critical patent/JP2009529502A/ja
Publication of JP2009529502A5 publication Critical patent/JP2009529502A5/ja
Pending legal-status Critical Current

Links

JP2008557568A 2006-03-09 2007-03-09 タンパク質凝集の障害の処置のためのシクロヘキサン多価アルコール処方物 Pending JP2009529502A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78052606P 2006-03-09 2006-03-09
US81986406P 2006-07-11 2006-07-11
US89766707P 2007-01-26 2007-01-26
PCT/CA2007/000395 WO2007101353A1 (en) 2006-03-09 2007-03-09 A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation

Publications (2)

Publication Number Publication Date
JP2009529502A JP2009529502A (ja) 2009-08-20
JP2009529502A5 true JP2009529502A5 (cg-RX-API-DMAC7.html) 2011-04-14

Family

ID=38474578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008557568A Pending JP2009529502A (ja) 2006-03-09 2007-03-09 タンパク質凝集の障害の処置のためのシクロヘキサン多価アルコール処方物

Country Status (14)

Country Link
US (1) US20100113613A1 (cg-RX-API-DMAC7.html)
EP (1) EP1996175A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009529502A (cg-RX-API-DMAC7.html)
KR (1) KR20090026247A (cg-RX-API-DMAC7.html)
CN (1) CN103054837A (cg-RX-API-DMAC7.html)
AU (1) AU2007222864A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0708725A2 (cg-RX-API-DMAC7.html)
CA (1) CA2644804A1 (cg-RX-API-DMAC7.html)
EA (1) EA200801967A1 (cg-RX-API-DMAC7.html)
IL (1) IL193970A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008011553A (cg-RX-API-DMAC7.html)
NZ (1) NZ571181A (cg-RX-API-DMAC7.html)
WO (1) WO2007101353A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200908303B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
CA2670405A1 (en) * 2006-11-24 2008-05-29 Waratah Pharmaceuticals Inc. Combination treatments for alzheimer's disease and related neurodegenerative diseases
DE102007030695A1 (de) * 2007-07-01 2009-01-08 Sciconcept Gmbh Co-Kristalle aus Harnstoff mit Amid- und/oder Harnstoffderivaten
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2012173808A1 (en) * 2011-06-03 2012-12-20 Elan Pharmaceuticals, Inc. Scyllo-inositol for the treatment of behavioral and psychiatric disorders
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
US20160129084A1 (en) * 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
US10188757B2 (en) 2013-10-22 2019-01-29 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ/ミクログリア
JP7202376B2 (ja) 2017-07-20 2023-01-11 エーゼットセラピーズ, インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
JP2021529771A (ja) 2018-07-02 2021-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリンナトリウムおよびα−ラクトースの粉末製剤
WO2020074944A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
MX2021006869A (es) 2018-12-10 2021-07-02 Massachusetts Gen Hospital Esteres de cromolin y usos de los mismos.
EP4132507A4 (en) 2020-04-06 2024-05-15 The General Hospital Corporation METHODS FOR TREATING CORONAVIRUS-INDUCED INFLAMMATORY CONDITIONS

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4515722A (en) * 1982-03-30 1985-05-07 Merck & Co., Inc. Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents
US4474806A (en) * 1982-05-10 1984-10-02 Merck & Co., Inc. Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents
US4952396A (en) * 1986-11-19 1990-08-28 Linus Pauling Institute Of Science & Medicine Method of using phytic acid for inhibiting tumor growth
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4758430A (en) * 1987-01-21 1988-07-19 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
SE8904355D0 (sv) * 1989-12-21 1989-12-21 Perstorp Ab Medicament
US5217959A (en) * 1990-09-06 1993-06-08 Robert Sabin Method of treating multiple sclerosis with phytic acid
US5112814A (en) * 1990-10-24 1992-05-12 Robert Sabin Method of treatment of Parkinson's disease using phytic acid
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
SE9102068L (sv) * 1991-07-03 1993-01-04 Perstorp Ab Derivat av inositol, kompositioner innehaallande dessa samt anvaendning daerav
SE469260B (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
NZ314111A (en) * 1992-10-05 1997-08-22 Virginia Tech Intell Prop Preparation of d-chiro-inositol by reducing d-chiro-3-inosose
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
DK0619369T3 (da) * 1993-04-05 2003-10-06 Aveve Nv Phytathydrolyse og enzymsammensætning til hydrolyse af phytat
ES2130440T3 (es) * 1993-08-11 1999-07-01 Hokko Chem Ind Co Proceso para producir d-(quiro)-inositol.
SE502574C2 (sv) * 1994-01-25 1995-11-13 Perstorp Ab En farmaceutisk komposition med förbättrad biotillgänglighet hos inositolfosfat
US5858326A (en) * 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US6232486B1 (en) * 1996-06-11 2001-05-15 Nutrimed Biotech Molecular probes and modulators for PI-PLC and PI 3-kinase
US5880099A (en) * 1996-09-20 1999-03-09 The Regents Of The University Of California Inositol polyphosphates and methods of using same
US5977078A (en) * 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
US5998485A (en) * 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
US6153603A (en) * 1997-06-27 2000-11-28 Perstorp Ab Method of treating angiogenesis in tumor tissue
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US6818430B1 (en) * 1999-06-07 2004-11-16 Hokko Chemical Industry Co., Ltd. Process for producing L-epi-2-inosose and novel process for producing epi-inositol
US6329256B1 (en) * 1999-09-24 2001-12-11 Advanced Micro Devices, Inc. Self-aligned damascene gate formation with low gate resistance
NZ518685A (en) * 1999-10-18 2004-04-30 Muscletech Res And Dev Inc Whey protein derivatives as food supplements that increase nitric oxide production in the body to enhance muscle size and strength
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
DE10031955A1 (de) * 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
AU2002236988A1 (en) * 2001-02-06 2002-08-19 Novartis Ag Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration
CA2437561A1 (en) * 2001-02-06 2002-08-15 Qlt Inc. Use of additional photodynamic therapy in the treatment of choroidal neovasculature
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
WO2003007944A1 (en) * 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
ATE458042T1 (de) * 2003-10-14 2010-03-15 Hokko Chem Ind Co Verfahren zur herstellung von scyllo-inositol
EP2186518A1 (en) * 2004-11-17 2010-05-19 McLaurin, Joanne Composition and methods for treatment of disorders of protein aggregation

Similar Documents

Publication Publication Date Title
JP2009529502A5 (cg-RX-API-DMAC7.html)
US8309535B2 (en) Compositions and methods to treat recurrent medical conditions
JP6353577B2 (ja) 組み合わせ組成物
JP2020023518A5 (cg-RX-API-DMAC7.html)
JP2018513188A5 (cg-RX-API-DMAC7.html)
JP2018507243A5 (cg-RX-API-DMAC7.html)
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2019517542A5 (cg-RX-API-DMAC7.html)
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
JP2010509326A5 (cg-RX-API-DMAC7.html)
JP2010065060A (ja) 心不全処置のための複合治療
JP2015515985A5 (cg-RX-API-DMAC7.html)
JP2013541583A5 (cg-RX-API-DMAC7.html)
JP5842058B2 (ja) 自閉症の治療における使用のためのクレンブテロール
JP2017533211A5 (cg-RX-API-DMAC7.html)
JP2019218379A5 (cg-RX-API-DMAC7.html)
JP2010538066A5 (cg-RX-API-DMAC7.html)
CA2563058C (en) Supportive treatment of liver disease
RU2008134143A (ru) Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения
US7825156B2 (en) Method of treating bipolar depression with a benzamide derivative
IL272834B1 (en) Compositions of amantadine, their preparation, and methods of use
RU2018131573A (ru) Способ лечения больных раком с тяжелой почечной недостаточностью
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤
JP2020503318A5 (cg-RX-API-DMAC7.html)
JP6420923B1 (ja) 医薬